May 11, 2022 / 08:00AM GMT
Magnus Corfitzen - Ascelia Pharma AB - CEO
Thank you, operator, and welcome, everyone, to the webcast for Ascelia's first-quarter report for 2022. So I'm Magnus Corfitzen, and I'm looking forward to updating you on our progress in this report.
So now please turn to page number two. We will be making certain forward-looking statements on this call, so please pay attention to this before we turn to page number three.
Ascelia Pharma is dedicated to improve the lives of people living with cancers by offering better treatment options. In particular, we focus on rare cancer conditions that are underserved. Our business model is to identify, develop, and commercialize novel drugs that address unmet medical needs within orphan oncology. We have two drugs in clinical development: only program Orviglance is an ongoing Phase 3 clinical study. It will be the only product targeting an addressable market of $500 million to $600 million end. Oncoral is ready to start Phase 2 in the treatment of gastric cancer based on encouraging results in Phase 1.
We're based in Malmö, in Sweden, and we
Q1 2022 Ascelia Pharma AB Earnings Call Transcript
May 11, 2022
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers